

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: Worl	d Journal	of Gastroen	terology
------------------------------	-----------	-------------	----------

Manuscript NO: 73485

Title: The impact of radiotherapy on the immune landscape in oesophageal

adenocarcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05872759 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Ireland

Manuscript submission date: 2021-12-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-12 12:02

Reviewer performed review: 2021-12-24 17:06

Review time: 12 Days and 5 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [] Anonymous [Y] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors propose an interesting study exploring the role of hypofractionation and immunotherapy in oesophageal adenocarcinoma. The results of this study provide a preclinical basis for randomised trials using hypofractionated treatment schedules and/or adding immunotherapy to conventional radiochemotherapy. The only useful addition, for future clinical use of the study results, is to discuss the possible patient toxicity scenarios of a hypofractionated approach + concomitant immunotherapy.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World	Journal of Gastroenterology
------------------------	-----------------------------

Manuscript NO: 73485

Title: The impact of radiotherapy on the immune landscape in oesophageal

adenocarcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03767590 Position: Editorial Board Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: Ireland

Manuscript submission date: 2021-12-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-25 23:19

Reviewer performed review: 2021-12-31 06:23

Review time: 5 Days and 7 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer statements

Peer-Review: [Y] Anonymous [] Onymous

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In the present manuscript, Donlon et al. evaluated the immunologic effect of hypofractionated radiotherapy in oesophageal adenocarcinoma. English in this paper is well written, and experiments are very well described. The figures are of quality and data are exposed in a clear manner. Specific major concerns: In the Figure 2, these experiments should be performed in the OAC xenograft model instead of cell lines because the anticancer effect of ICI is induced in the situation of the presence of CD8+ T cells. What is the scientific rationale in the experimental design? If the experimental design in Figure 2 has a scientific rationale, what mechanisms might explain the induction of anti-cancer efficacy of the combined RT and ICI in an experimental system without CD8+ T cell? Some minor concerns: Can you provide the original dot plots of Flow cytometry in Figure 1?